IDRA - Idera Pharmaceuticals GAAP EPS of -$0.06 revenue of $0.05M November, 14 2022 06:35 PM Idera Pharmaceuticals Inc. Idera Pharmaceuticals press release ( NASDAQ: IDRA ): Q3 GAAP EPS of -$0.06. Revenue of $0.05M. The Company’s pro forma cash position as of September 30, 2022 was $26.8 million. For further details see: Idera Pharmaceuticals GAAP EPS of -$0.06, revenue of $0.05M